{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:20:09Z","timestamp":1783354809099,"version":"3.54.6"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01516-9","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:34:43Z","timestamp":1778603683000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impaired iron balance and erythrocytosis: a complex relationship"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6961-5096","authenticated-orcid":false,"given":"Beno\u00eet","family":"Gendrot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Peyssonnaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5915-6910","authenticated-orcid":false,"given":"Isabelle","family":"Plo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Vaulont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-393X","authenticated-orcid":false,"given":"Guillemette","family":"Fouquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"1516_CR1","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1056\/NEJMra1406186","volume":"376","author":"JL Spivak","year":"2017","unstructured":"Spivak JL. Myeloproliferative Neoplasms. N Engl J Med. 2017;376:2168\u201381.","journal-title":"N Engl J Med"},{"key":"1516_CR2","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144\u20138.","journal-title":"Nature"},{"key":"1516_CR3","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","volume":"21","author":"A Pardanani","year":"2007","unstructured":"Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007;21:1960\u20133.","journal-title":"Leukemia"},{"key":"1516_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459\u201368.","journal-title":"N Engl J Med"},{"key":"1516_CR5","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1182\/blood.2019001385","volume":"134","author":"AB Patel","year":"2019","unstructured":"Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, et al. JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood. 2019;134:2388\u201398.","journal-title":"Blood"},{"key":"1516_CR6","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMc1006966","volume":"363","author":"TL Lasho","year":"2010","unstructured":"Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med. 2010;363:1189\u201390.","journal-title":"N Engl J Med"},{"key":"1516_CR7","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","volume":"117","author":"F Passamonti","year":"2011","unstructured":"Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011;117:2813\u20136.","journal-title":"Blood"},{"key":"1516_CR8","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/ajh.22063","volume":"86","author":"LM Scott","year":"2011","unstructured":"Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol. 2011;86:668\u201376.","journal-title":"Am J Hematol"},{"key":"1516_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22\u201333.","journal-title":"N Engl J Med"},{"key":"1516_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.clml.2019.06.001","volume":"19","author":"MR Grunwald","year":"2019","unstructured":"Grunwald MR, Burke JM, Kuter DJ, Gerds AT, Stein B, Walshauser MA, et al. Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study. Clin lymphoma, myeloma Leuk. 2019;19:579\u201384.e1.","journal-title":"Clin lymphoma, myeloma Leuk"},{"key":"1516_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00277-015-2548-z","volume":"95","author":"ML Randi","year":"2016","unstructured":"Randi ML, Bertozzi I, Cosi E, Santarossa C, Peroni E, Fabris F. Idiopathic erythrocytosis: a study of a large cohort with a long follow-up. Ann Hematol. 2016;95:233\u20137.","journal-title":"Ann Hematol"},{"key":"1516_CR12","doi-asserted-by":"crossref","unstructured":"Rezasoltani M, Herrick J, Rangan A, Zhang X, Pardanani A, Tefferi A, et al. Next-generation sequencing panel for hereditary erythrocytosis identifies genomic variants in over half of adults with otherwise unexplained erythrocytosis. Blood. 2025; Volume 146:Page 2877, ISSN 0006-4971.","DOI":"10.1182\/blood-2025-2877"},{"key":"1516_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1006\/bcmd.2002.0573","volume":"29","author":"G Nicolas","year":"2002","unstructured":"Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis. 2002;29:327\u201335.","journal-title":"Blood Cells Mol Dis"},{"key":"1516_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev.nutr.26.061505.111303","volume":"26","author":"E Nemeth","year":"2006","unstructured":"Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr. 2006;26:323\u201342.","journal-title":"Annu Rev Nutr"},{"key":"1516_CR15","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3324\/haematol.2009.020123","volume":"95","author":"S Marro","year":"2010","unstructured":"Marro S, Chiabrando D, Messana E, Stolte J, Turco E, Tolosano E, et al. Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 and a MARE\/ARE sequence motif at position -7007 of the FPN1 promoter. Haematologica. 2010;95:1261\u20138.","journal-title":"Haematologica"},{"key":"1516_CR16","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1182\/blood-2003-04-1250","volume":"102","author":"MD Knutson","year":"2003","unstructured":"Knutson MD, Vafa MR, Haile DJ, Wessling-Resnick M. Iron loading and erythrophagocytosis increase ferroportin 1 (FPN1) expression in J774 macrophages. Blood. 2003;102:4191\u20137.","journal-title":"Blood"},{"key":"1516_CR17","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1182\/blood-2014-08-595256","volume":"125","author":"C Guida","year":"2015","unstructured":"Guida C, Altamura S, Klein FA, Galy B, Boutros M, Ulmer AJ, et al. A novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. Blood. 2015;125:2265\u201375.","journal-title":"Blood"},{"key":"1516_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.cmet.2009.03.006","volume":"9","author":"DL Zhang","year":"2009","unstructured":"Zhang DL, Hughes RM, Ollivierre-Wilson H, Ghosh MC, Rouault TA. A ferroportin transcript that lacks an iron-responsive element enables duodenal and erythroid precursor cells to evade translational repression. Cell Metab. 2009;9:461\u201373.","journal-title":"Cell Metab"},{"key":"1516_CR19","first-page":"1595","volume":"90","author":"L Cianetti","year":"2005","unstructured":"Cianetti L, Segnalini P, Calzolari A, Morsilli O, Felicetti F, Ramoni C, et al. Expression of alternative transcripts of ferroportin-1 during human erythroid differentiation. Haematologica. 2005;90:1595\u2013606.","journal-title":"Haematologica"},{"key":"1516_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41580-023-00648-1","volume":"25","author":"B Galy","year":"2024","unstructured":"Galy B, Conrad M, Muckenthaler M. Mechanisms controlling cellular and systemic iron homeostasis. Nat Rev Mol Cell Biol. 2024;25:133\u201355.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1516_CR21","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1074\/jbc.M008923200","volume":"276","author":"C Pigeon","year":"2001","unstructured":"Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276:7811\u20139.","journal-title":"J Biol Chem"},{"key":"1516_CR22","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI200420945","volume":"113","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Investig. 2004;113:1271\u20136.","journal-title":"J Clin Investig"},{"key":"1516_CR23","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1172\/JCI0215686","volume":"110","author":"G Nicolas","year":"2002","unstructured":"Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110:1037\u201344.","journal-title":"J Clin Invest"},{"key":"1516_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","volume":"30","author":"WG Kaelin Jr","year":"2008","unstructured":"Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30:393\u2013402.","journal-title":"Mol Cell"},{"key":"1516_CR25","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1182\/blood-2010-02-270322","volume":"116","author":"PP Kapitsinou","year":"2010","unstructured":"Kapitsinou PP, Liu Q, Unger TL, Rha J, Davidoff O, Keith B, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood. 2010;116:3039\u201348.","journal-title":"Blood"},{"key":"1516_CR26","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1053\/j.gastro.2013.12.031","volume":"146","author":"YM Shah","year":"2014","unstructured":"Shah YM, Xie L. Hypoxia-inducible factors link iron homeostasis and erythropoiesis. Gastroenterology. 2014;146:630\u201342.","journal-title":"Gastroenterology"},{"key":"1516_CR27","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2007-08-106195","volume":"111","author":"JP Pinto","year":"2008","unstructured":"Pinto JP, Ribeiro S, Pontes H, Thowfeequ S, Tosh D, Carvalho F, et al. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C\/EBPalpha. Blood. 2008;111:5727\u201333.","journal-title":"Blood"},{"key":"1516_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2024.119800","volume":"1871","author":"RE Maltaneri","year":"2024","unstructured":"Maltaneri RE, Chamorro ME, Gionco SE, Nesse AB, Vittori DC. Erythropoietin enhances iron bioavailability in HepG2 cells by downregulating hepcidin through mTOR, C\/EBP\u03b1 and HIF-1\u03b1. Biochim Biophys Acta Mol Cell Res. 2024;1871:119800.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1516_CR29","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3324\/haematol.2011.056119","volume":"97","author":"M Mastrogiannaki","year":"2012","unstructured":"Mastrogiannaki M, Matak P, Mathieu JR, Delga S, Mayeux P, Vaulont S, et al. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica. 2012;97:827\u201334.","journal-title":"Haematologica"},{"key":"1516_CR30","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1172\/JCI63924","volume":"122","author":"Q Liu","year":"2012","unstructured":"Liu Q, Davidoff O, Niss K, Haase VH. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Investig. 2012;122:4635\u201344.","journal-title":"J Clin Investig"},{"key":"1516_CR31","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1128\/MCB.00723-12","volume":"32","author":"ER Anderson","year":"2012","unstructured":"Anderson ER, Taylor M, Xue X, Martin A, Moons DS, Omary MB, et al. The hypoxia-inducible factor-C\/EBP\u03b1 axis controls ethanol-mediated hepcidin repression. Mol Cell Biol. 2012;32:4068\u201377.","journal-title":"Mol Cell Biol"},{"key":"1516_CR32","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/ng.2996","volume":"46","author":"L Kautz","year":"2014","unstructured":"Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46:678\u201384.","journal-title":"Nat Genet"},{"key":"1516_CR33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/ng1019","volume":"32","author":"SO Ang","year":"2002","unstructured":"Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002;32:614\u201321.","journal-title":"Nat Genet"},{"key":"1516_CR34","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/ajh.27021","volume":"98","author":"BN Shah","year":"2023","unstructured":"Shah BN, Zhang X, Sergueeva AI, Miasnikova GY, Ganz T, Prchal JT, et al. Increased transferrin protects from thrombosis in Chuvash erythrocytosis. Am J Hematol. 2023;98:1532\u20139.","journal-title":"Am J Hematol"},{"key":"1516_CR35","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1182\/blood.2020009138","volume":"137","author":"MC Ghosh","year":"2021","unstructured":"Ghosh MC, Zhang DL, Ollivierre WH, Noguchi A, Springer DA, Linehan WM, et al. Therapeutic inhibition of HIF-2\u03b1 reverses polycythemia and pulmonary hypertension in murine models of human diseases. Blood. 2021;137:2509\u201319.","journal-title":"Blood"},{"key":"1516_CR36","doi-asserted-by":"publisher","first-page":"10289","DOI":"10.1073\/pnas.0603124103","volume":"103","author":"J Truksa","year":"2006","unstructured":"Truksa J, Peng H, Lee P, Beutler E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci USA. 2006;103:10289\u201393.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1516_CR37","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1172\/JCI31342","volume":"117","author":"JL Babitt","year":"2007","unstructured":"Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Investig. 2007;117:1933\u20139.","journal-title":"J Clin Investig"},{"key":"1516_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3389\/fphar.2014.00104","volume":"5","author":"AB Core","year":"2014","unstructured":"Core AB, Canali S, Babitt JL. Hemojuvelin and bone morphogenetic protein (BMP) signaling in iron homeostasis. Front Pharmacol. 2014;5:104.","journal-title":"Front Pharmacol"},{"key":"1516_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cmet.2007.11.016","volume":"7","author":"PJ Schmidt","year":"2008","unstructured":"Schmidt PJ, Toran PT, Giannetti AM, Bjorkman PJ, Andrews NC. The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metab. 2008;7:205\u201314.","journal-title":"Cell Metab"},{"key":"1516_CR40","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1182\/blood-2010-04-281360","volume":"116","author":"H Forejtnikova","year":"2010","unstructured":"Forejtnikova H, Vieillevoye M, Zermati Y, Lambert M, Pellegrino RM, Guihard S, et al. Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis. Blood. 2010;116:5357\u201367.","journal-title":"Blood"},{"key":"1516_CR41","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1182\/blood-2014-08-596254","volume":"125","author":"A Nai","year":"2015","unstructured":"Nai A, Lidonnici MR, Rausa M, Mandelli G, Pagani A, Silvestri L, et al. The second transferrin receptor regulates red blood cell production in mice. Blood. 2015;125:1170\u20139.","journal-title":"Blood"},{"key":"1516_CR42","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1182\/blood-2014-12-617571","volume":"125","author":"K Pantopoulos","year":"2015","unstructured":"Pantopoulos K. TfR2 links iron metabolism and erythropoiesis. Blood. 2015;125:1055\u20136.","journal-title":"Blood"},{"key":"1516_CR43","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.cmet.2008.09.012","volume":"8","author":"L Silvestri","year":"2008","unstructured":"Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 2008;8:502\u201311.","journal-title":"Cell Metab"},{"key":"1516_CR44","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood-2015-07-658419","volume":"126","author":"L Kautz","year":"2015","unstructured":"Kautz L, Jung G, Du X, Gabayan V, Chapman J, Nasoff M, et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of beta-thalassemia. Blood. 2015;126:2031\u20137.","journal-title":"Blood"},{"key":"1516_CR45","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/ng.130","volume":"40","author":"KE Finberg","year":"2008","unstructured":"Finberg KE, Heeney MM, Campagna DR, Aydinok Y, Pearson HA, Hartman KR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008;40:569\u201371.","journal-title":"Nat Genet"},{"key":"1516_CR46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1053\/j.gastro.2010.06.013","volume":"139","author":"A Pietrangelo","year":"2010","unstructured":"Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010;139:393\u2013408.e1-2.","journal-title":"Gastroenterology"},{"key":"1516_CR47","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1155\/2014\/468521","volume":"28","author":"M Kelley","year":"2014","unstructured":"Kelley M, Joshi N, Xie Y, Borgaonkar M. Iron overload is rare in patients homozygous for the H63D mutation. Can J Gastroenterol Hepatol. 2014;28:198\u2013202.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1516_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.16","volume":"4","author":"P Brissot","year":"2018","unstructured":"Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Lor\u00e9al O. Haemochromatosis. Nat Rev Dis Prim. 2018;4:18016.","journal-title":"Nat Rev Dis Prim"},{"key":"1516_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0140-6736(02)07447-0","volume":"359","author":"E Beutler","year":"2002","unstructured":"Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G-> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002;359:211\u20138.","journal-title":"Lancet"},{"key":"1516_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00552-x","volume":"11","author":"D Liu","year":"2021","unstructured":"Liu D, Xu Z, Zhang P, Qin T, Li B, Qu S, et al. Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera. Blood cancer J. 2021;11:154.","journal-title":"Blood cancer J"},{"key":"1516_CR51","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ajh.23694","volume":"89","author":"T Barbui","year":"2014","unstructured":"Barbui T, Thiele J, Carobbio A, Guglielmelli P, Rambaldi A, Vannucchi AM, et al. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2-mutated patients. Am J Hematol. 2014;89:588\u201390.","journal-title":"Am J Hematol"},{"key":"1516_CR52","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ajh.23585","volume":"89","author":"T Barbui","year":"2014","unstructured":"Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2014;89:52\u20134.","journal-title":"Am J Hematol"},{"key":"1516_CR53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ajh.23617","volume":"89","author":"T Barbui","year":"2014","unstructured":"Barbui T, Thiele J, Carobbio A, Gisslinger H, Finazzi G, Rumi E, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol. 2014;89:199\u2013202.","journal-title":"Am J Hematol"},{"key":"1516_CR54","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/ejh.12645","volume":"96","author":"JJ Pratt","year":"2016","unstructured":"Pratt JJ, Khan KS. Non-anaemic iron deficiency - a disease looking for recognition of diagnosis: a systematic review. Eur J Haematol. 2016;96:618\u201328.","journal-title":"Eur J Haematol"},{"key":"1516_CR55","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1136\/bmj.326.7399.1124","volume":"326","author":"F Verdon","year":"2003","unstructured":"Verdon F, Burnand B, Stubi CL, Bonard C, Graff M, Michaud A, et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ. 2003;326:1124.","journal-title":"BMJ"},{"key":"1516_CR56","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/ajh.24417","volume":"91","author":"G Rishi","year":"2016","unstructured":"Rishi G, Secondes ES, Wallace DF, Subramaniam VN. Hematopoietic deletion of transferrin receptor 2 in mice leads to a block in erythroid differentiation during iron-deficient anemia. Am J Hematol. 2016;91:812\u20138.","journal-title":"Am J Hematol"},{"key":"1516_CR57","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1182\/bloodadvances.2016003772","volume":"1","author":"S Khalil","year":"2017","unstructured":"Khalil S, Holy M, Grado S, Fleming R, Kurita R, Nakamura Y, et al. A specialized pathway for erythroid iron delivery through lysosomal trafficking of transferrin receptor 2. Blood Adv. 2017;1:1181\u201394.","journal-title":"Blood Adv"},{"key":"1516_CR58","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1084\/jem.20170396","volume":"215","author":"S Khalil","year":"2018","unstructured":"Khalil S, Delehanty L, Grado S, Holy M, White Z 3rd, Freeman K, et al. Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med. 2018;215:661\u201379.","journal-title":"J Exp Med"},{"key":"1516_CR59","doi-asserted-by":"publisher","first-page":"22865","DOI":"10.1074\/jbc.M603876200","volume":"281","author":"M Sanchez","year":"2006","unstructured":"Sanchez M, Galy B, Dandekar T, Bengert P, Vainshtein Y, Stolte J, et al. Iron regulation and the cell cycle: identification of an iron-responsive element in the 3\u2019-untranslated region of human cell division cycle 14A mRNA by a refined microarray-based screening strategy. J Biol Chem. 2006;281:22865\u201374.","journal-title":"J Biol Chem"},{"key":"1516_CR60","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1182\/blood-2009-10-251496","volume":"116","author":"GC Bullock","year":"2010","unstructured":"Bullock GC, Delehanty LL, Talbot AL, Gonias SL, Tong WH, Rouault TA, et al. Iron control of erythroid development by a novel aconitase-associated regulatory pathway. Blood. 2010;116:97\u2013108.","journal-title":"Blood"},{"key":"1516_CR61","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.beha.2005.07.011","volume":"19","author":"R Landolfi","year":"2006","unstructured":"Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol. 2006;19:617\u201333.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1516_CR62","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1046\/j.1365-2141.2002.03380.x","volume":"117","author":"G Torgano","year":"2002","unstructured":"Torgano G, Mandelli C, Massaro P, Abbiati C, Ponzetto A, Bertinieri G, et al. Gastroduodenal lesions in polycythaemia vera: frequency and role of Helicobacter pylori. Br J Haematol. 2002;117:198\u2013202.","journal-title":"Br J Haematol"},{"key":"1516_CR63","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/BF00251637","volume":"3","author":"E Sch\u00e4chner","year":"1978","unstructured":"Sch\u00e4chner E, Ronen M, Pinkhas J, Djaldetti M. Iron absorption in patients with polycythemia vera: a comparative study using the whole-body counter and the ferrous sulfate absorption test. Eur J Nucl Med. 1978;3:125\u20137.","journal-title":"Eur J Nucl Med"},{"key":"1516_CR64","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/102476","volume":"2015","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch HC, Bj\u00f8rn ME. MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediators Inflamm. 2015;2015:102476.","journal-title":"Mediators Inflamm"},{"key":"1516_CR65","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/ejh.12150","volume":"91","author":"P Tarkun","year":"2013","unstructured":"Tarkun P, Mehtap O, Ateso\u011flu EB, Geduk A, Musul MM, Hacihanefioglu A. Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia. Eur J Haematol. 2013;91:228\u201335.","journal-title":"Eur J Haematol"},{"key":"1516_CR66","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1124\/mol.105.018481","volume":"69","author":"C Lee","year":"2006","unstructured":"Lee C, Lim HK, Sakong J, Lee YS, Kim JR, Baek SH. Janus kinase-signal transducer and activator of transcription mediates phosphatidic acid-induced interleukin (IL)-1beta and IL-6 production. Mol Pharmacol. 2006;69:1041\u20137.","journal-title":"Mol Pharmacol"},{"key":"1516_CR67","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","volume":"32","author":"YZ Ginzburg","year":"2018","unstructured":"Ginzburg YZ, Feola M, Zimran E, Varkonyi J, Ganz T, Hoffman R. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018;32:2105\u201316.","journal-title":"Leukemia"},{"key":"1516_CR68","first-page":"3199","volume":"141","author":"C Bennett","year":"2023","unstructured":"Bennett C, Jackson VE, Pettikiriarachchi A, Hayman T, Schaeper U, Moir-Meyer G, et al. Iron homeostasis governs erythroid phenotype in polycythemia vera. Blood. 2023;141:3199\u2013214.","journal-title":"Blood"},{"key":"1516_CR69","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood-2015-12-689216","volume":"128","author":"J Grisouard","year":"2016","unstructured":"Grisouard J, Li S, Kubovcakova L, Rao TN, Meyer SC, Lundberg P, et al. JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood. 2016;128:839\u201351.","journal-title":"Blood"},{"key":"1516_CR70","first-page":"2127","volume":"141","author":"J Stetka","year":"2023","unstructured":"Stetka J, Usart M, Kubovcakova L, Rai S, Rao TN, Sutter J, et al. Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood. 2023;141:2127\u201340.","journal-title":"Blood"},{"key":"1516_CR71","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.leukres.2017.01.032","volume":"56","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Harrison CN, Kiladjian JJ, Miller C, Naim AB, Paranagama DC, et al. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Leuk Res. 2017;56:52\u20139.","journal-title":"Leuk Res"},{"key":"1516_CR72","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1034\/j.1600-0609.2001.t01-1-00481.x","volume":"67","author":"G Porto","year":"2001","unstructured":"Porto G, Cardoso CS, Gordeuk V, Cruz E, Fraga J, Areias J, et al. Clinical and genetic heterogeneity in hereditary haemochromatosis: association between lymphocyte counts and expression of iron overload. Eur J Haematol. 2001;67:110\u20138.","journal-title":"Eur J Haematol"},{"key":"1516_CR73","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/10428190290011930","volume":"43","author":"MT Dorak","year":"2002","unstructured":"Dorak MT, Burnett AK, Worwood M. Hemochromatosis gene in leukemia and lymphoma. Leuk lymphoma. 2002;43:467\u201377.","journal-title":"Leuk lymphoma"},{"key":"1516_CR74","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/1097-0142(197902)43:2<690::AID-CNCR2820430241>3.0.CO;2-R","volume":"43","author":"B Raphael","year":"1979","unstructured":"Raphael B, Cooperberg AA, Niloff P. The triad of hemochromatosis, hepatoma and erythrocytosis. Cancer. 1979;43:690\u20134.","journal-title":"Cancer"},{"key":"1516_CR75","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0022-2143(00)70026-6","volume":"135","author":"JC Barton","year":"2000","unstructured":"Barton JC, Bertoli LF, Rothenberg BE. Peripheral blood erythrocyte parameters in hemochromatosis: evidence for increased erythrocyte hemoglobin content. J Lab Clin Med. 2000;135:96\u2013104.","journal-title":"J Lab Clin Med"},{"key":"1516_CR76","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/clinchem\/46.2.162","volume":"46","author":"E Rossi","year":"2000","unstructured":"Rossi E, Olynyk JK, Cullen DJ, Papadopoulos G, Bulsara M, Summerville L, et al. Compound heterozygous hemochromatosis genotype predicts increased iron and erythrocyte indices in women. Clin Chem. 2000;46:162\u20136.","journal-title":"Clin Chem"},{"key":"1516_CR77","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7326\/0003-4819-133-5-200009050-00008","volume":"133","author":"E Beutler","year":"2000","unstructured":"Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med. 2000;133:329\u201337.","journal-title":"Ann Intern Med"},{"key":"1516_CR78","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1046\/j.1365-2141.2003.04215.x","volume":"120","author":"E Beutler","year":"2003","unstructured":"Beutler E, Felitti V, Gelbart T, Waalen J. Haematological effects of the C282Y HFE mutation in homozygous and heterozygous states among subjects of northern and southern European ancestry. Br J Haematol. 2003;120:887\u201393.","journal-title":"Br J Haematol"},{"key":"1516_CR79","doi-asserted-by":"publisher","first-page":"422","DOI":"10.14740\/jocmr3816","volume":"11","author":"S Asif","year":"2019","unstructured":"Asif S, Begemann M, Raza S. Polycythemia in Patients With Hereditary Hemochromatosis: Real or Myth? J Clin Med Res. 2019;11:422\u20137.","journal-title":"J Clin Med Res"},{"key":"1516_CR80","volume":"12","author":"AA Khan","year":"2020","unstructured":"Khan AA, Hadi Y, Hassan A, Kupec J. Polycythemia and Anemia in Hereditary Hemochromatosis. Cureus. 2020;12:e7607.","journal-title":"Cureus"},{"key":"1516_CR81","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.3390\/cells11142152","volume":"11","author":"T Kawabata","year":"2022","unstructured":"Kawabata T. Iron-induced oxidative stress in human diseases. Cells. 2022;11:2152.","journal-title":"Cells"},{"key":"1516_CR82","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/MOH.0000000000000495","volume":"26","author":"A Matte","year":"2019","unstructured":"Matte A, De Franceschi L. Oxidation and erythropoiesis. Curr Opin Hematol. 2019;26:145\u201351.","journal-title":"Curr Opin Hematol"},{"key":"1516_CR83","doi-asserted-by":"crossref","unstructured":"Franchini M, de Matteis G, Federici F, Solero P, Veneri D. Analysis of hemochromatosis gene mutations in 52 consecutive patients with polycythemia vera. Hematology. 2004;9:413\u20134.","DOI":"10.1080\/10245330400001934"},{"key":"1516_CR84","first-page":"131","volume":"87","author":"J Hannuksela","year":"2002","unstructured":"Hannuksela J, Savolainen ER, Koistinen P, Parkkila S. Prevalence of HFE genotypes, C282Y and H63D, in patients with hematologic disorders. Haematologica. 2002;87:131\u20135.","journal-title":"Haematologica"},{"key":"1516_CR85","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4907","volume":"9","author":"A Radwan","year":"2021","unstructured":"Radwan A, Othman I. Hereditary hemochromatosis and JAK2-positive polycythemia vera. Clin Case Rep. 2021;9:e04907.","journal-title":"Clin Case Rep"},{"key":"1516_CR86","doi-asserted-by":"publisher","unstructured":"Kiper Unal H, Cetintepe T, Solmaz S, Subasioglu A, Payzin K. PB2251: Two Polycythemia Vera patients with a diagnosis of concomitant Hereditary Hemochromatosis. HemaSphere. 2022;6:2121\u20132. https:\/\/doi.org\/10.1097\/01.HS9.0000851832.93962.79.","DOI":"10.1097\/01.HS9.0000851832.93962.79"},{"key":"1516_CR87","doi-asserted-by":"crossref","unstructured":"Singh P, Toom S, Shrivastava MS, Solomon WBJB. A rare combination of genetic mutations in an elderly female: a diagnostic dilemma! 2016;128:5487.","DOI":"10.1182\/blood.V128.22.5487.5487"},{"key":"1516_CR88","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1158\/1055-9965.EPI-08-0359","volume":"18","author":"H Andrikovics","year":"2009","unstructured":"Andrikovics H, Meggyesi N, Szilvasi A, Tamaska J, Halm G, Lueff S, et al. HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative disease. Cancer Epidemiol, Biomark Prev. 2009;18:929\u201334.","journal-title":"Cancer Epidemiol, Biomark Prev"},{"key":"1516_CR89","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1182\/blood.2023020509","volume":"141","author":"D Girelli","year":"2023","unstructured":"Girelli D, Busti F. Manipulating hepcidin in polycythemia vera. Blood. 2023;141:3132\u20134.","journal-title":"Blood"},{"key":"1516_CR90","first-page":"92","volume":"28","author":"SE Langabeer","year":"2017","unstructured":"Langabeer SE. Hemochromatosis, Erythrocytosis and the JAK2 p.V617F Mutation. Ejifcc. 2017;28:92\u20133.","journal-title":"Ejifcc"},{"key":"1516_CR91","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/jha2.222","volume":"2","author":"EJ van Bommel","year":"2021","unstructured":"van Bommel EJ, Kelder D, Hoeks MP, Herbers AH. The development of polycythemia vera after phlebotomy treatment for hereditary haemochromatosis. EJHaem. 2021;2:537\u20138.","journal-title":"EJHaem"},{"key":"1516_CR92","first-page":"159","volume":"40","author":"Y Najean","year":"1998","unstructured":"Najean Y, Rain JD, Billotey C. Epidemiological data in polycythaemia vera: a study of 842 cases. Hematol Cell Ther. 1998;40:159\u201365.","journal-title":"Hematol Cell Ther"},{"key":"1516_CR93","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/bjh.14555","volume":"181","author":"G Biagetti","year":"2018","unstructured":"Biagetti G, Catherwood M, Robson N, Bertozzi I, Cosi E, McMullin MF, et al. HFE mutations in idiopathic erythrocytosis. Br J Haematol. 2018;181:270\u20132.","journal-title":"Br J Haematol"},{"key":"1516_CR94","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23715","volume":"35","author":"A Kristan","year":"2021","unstructured":"Kristan A, Ga\u0161per\u0161i\u010d J, Re\u017een T, Kunej T, Koli\u010d R, Vuga A, et al. Genetic analysis of 39 erythrocytosis and hereditary hemochromatosis-associated genes in the Slovenian family with idiopathic erythrocytosis. J Clin Lab Anal. 2021;35:e23715.","journal-title":"J Clin Lab Anal"},{"key":"1516_CR95","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1111\/bjh.15931","volume":"186","author":"C Gurnari","year":"2019","unstructured":"Gurnari C, Lombardi AM, Cosi E, Biagetti G, Buccisano F, Franceschini L, et al. Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations. Br J Haematol. 2019;186:e100\u2013e3.","journal-title":"Br J Haematol"},{"key":"1516_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1440712","volume":"11","author":"S An\u017eej Doma","year":"2024","unstructured":"An\u017eej Doma S, Kralji\u0107 N, Kristan A, Debeljak N, Maver A, Paji\u010d T, et al. Utility of next-generation sequencing in identifying congenital erythrocytosis in patients with idiopathic erythrocytosis. Front Med. 2024;11:1440712.","journal-title":"Front Med"},{"key":"1516_CR97","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/bjh.15631","volume":"185","author":"B Burlet","year":"2019","unstructured":"Burlet B, Bourgeois V, Buriller C, Aral B, Airaud F, Garrec C, et al. High HFE mutation incidence in idiopathic erythrocytosis. Br J Haematol. 2019;185:794\u20135.","journal-title":"Br J Haematol"},{"key":"1516_CR98","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1097\/MPH.0000000000002126","volume":"44","author":"B Kaczorowska-Hac","year":"2022","unstructured":"Kaczorowska-Hac B, Luszczyk M, Wasilewska E, Antosiewicz J, Kaczor JJ. Erythropoietin Concentration in Boys With p.His63Asp Polymorphism of the HFE Gene. J Pediatr Hematol \/Oncol. 2022;44:e68\u2013e73.","journal-title":"J Pediatr Hematol \/Oncol"},{"key":"1516_CR99","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1182\/blood-2010-09-307462","volume":"117","author":"P Ramos","year":"2011","unstructured":"Ramos P, Guy E, Chen N, Proenca CC, Gardenghi S, Casu C, et al. Enhanced erythropoiesis in Hfe-KO mice indicates a role for Hfe in the modulation of erythroid iron homeostasis. Blood. 2011;117:1379\u201389.","journal-title":"Blood"},{"key":"1516_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biochi.2015.09.028","volume":"119","author":"O Hermine","year":"2015","unstructured":"Hermine O, Dine G, Genty V, Marquet LA, Fumagalli G, Tafflet M, et al. Eighty percent of French sport winners in Olympic, World and Europeans competitions have mutations in the hemochromatosis HFE gene. Biochimie. 2015;119:1\u20135.","journal-title":"Biochimie"},{"key":"1516_CR101","doi-asserted-by":"publisher","first-page":"101291","DOI":"10.1016\/j.gendis.2024.101291","volume":"12","author":"A Benetti","year":"2025","unstructured":"Benetti A, Bertozzi I, Randi ML. TFR2 gene alterations in idiopathic erythrocytosis reinforce a possible relation between erythrocytosis and iron metabolism. Genes Dis. 2025;12:101291.","journal-title":"Genes Dis"},{"key":"1516_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0939-7","volume":"17","author":"B Psaila","year":"2016","unstructured":"Psaila B, Barkas N, Iskander D, Roy A, Anderson S, Ashley N, et al. Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways. Genome Biol. 2016;17:83.","journal-title":"Genome Biol"},{"key":"1516_CR103","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ng.3465","volume":"48","author":"HH Jabara","year":"2016","unstructured":"Jabara HH, Boyden SE, Chou J, Ramesh N, Massaad MJ, Benson H, et al. A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency. Nat Genet. 2016;48:74\u20138.","journal-title":"Nat Genet"},{"key":"1516_CR104","doi-asserted-by":"crossref","unstructured":"Migliaccio AF, Tirelli V, Masiello F, Sanchez M, Whitsett C, Migliaccio G. High Levels of CD44 Expression Identify Hematopoietic Cells Capable of Generating Great Numbers of Erythroid Cells Under HEMA Conditions. ASH Annual Meeting Abstracts. 2010.","DOI":"10.1182\/blood.V116.21.3349.3349"},{"key":"1516_CR105","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41557-020-0513-5","volume":"12","author":"S M\u00fcller","year":"2020","unstructured":"M\u00fcller S, Sindikubwabo F, Ca\u00f1eque T, Lafon A, Versini A, Lombard B, et al. CD44 regulates epigenetic plasticity by mediating iron endocytosis. Nat Chem. 2020;12:929\u201338.","journal-title":"Nat Chem"},{"key":"1516_CR106","doi-asserted-by":"publisher","first-page":"17413","DOI":"10.1073\/pnas.0909296106","volume":"106","author":"K Chen","year":"2009","unstructured":"Chen K, Liu J, Heck S, Chasis JA, An X, Mohandas N. Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis. Proc Natl Acad Sci USA. 2009;106:17413\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1516_CR107","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1182\/blood-2012-09-456079","volume":"121","author":"J Liu","year":"2013","unstructured":"Liu J, Zhang J, Ginzburg Y, Li H, Xue F, De Franceschi L, et al. Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis. Blood. 2013;121:e43\u20139.","journal-title":"Blood"},{"key":"1516_CR108","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","volume":"129","author":"M Asshoff","year":"2017","unstructured":"Asshoff M, Petzer V, Warr MR, Haschka D, Tymoszuk P, Demetz E, et al. Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017;129:1823\u201330.","journal-title":"Blood"},{"key":"1516_CR109","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/MOH.0000000000000747","volume":"30","author":"S Handa","year":"2023","unstructured":"Handa S, Ginzburg Y, Hoffman R, Kremyanskaya M. Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis. Curr Opin Hematol. 2023;30:45\u201352.","journal-title":"Curr Opin Hematol"},{"key":"1516_CR110","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2015-10-676742","volume":"128","author":"C Casu","year":"2016","unstructured":"Casu C, Oikonomidou PR, Chen H, Nandi V, Ginzburg Y, Prasad P, et al. Minihepcidin peptides as disease modifiers in mice affected by \u03b2-thalassemia and polycythemia vera. Blood. 2016;128:265\u201376.","journal-title":"Blood"},{"key":"1516_CR111","doi-asserted-by":"publisher","first-page":"e0251995","DOI":"10.1371\/journal.pone.0251995","volume":"16","author":"C Casu","year":"2021","unstructured":"Casu C, Liu A, De Rosa G, Low A, Suzuki A, Sinha S, et al. Tmprss6-ASO as a tool for the treatment of Polycythemia Vera mice. PloS One. 2021;16:e0251995.","journal-title":"PloS One"},{"key":"1516_CR112","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1182\/blood-2021-154118","volume":"138","author":"R Taranath","year":"2021","unstructured":"Taranath R, Zhao L, Vengalam J, Lee L, Tang T, Dion C, et al. Regulation of iron homeostasis and efficacy of Rusfertide analog peptide in a mouse model for Polycythemia Vera. Blood. 2021;138:2006.","journal-title":"Blood"},{"key":"1516_CR113","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood-2017-11-737411","volume":"131","author":"C Casu","year":"2018","unstructured":"Casu C, Nemeth E, Rivella S. Hepcidin agonists as therapeutic tools. Blood. 2018;131:1790\u20134.","journal-title":"Blood"},{"key":"1516_CR114","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa2308809","volume":"390","author":"M Kremyanskaya","year":"2024","unstructured":"Kremyanskaya M, Kuykendall AT, Pemmaraju N, Ritchie EK, Gotlib J, Gerds A, et al. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. N Engl J Med. 2024;390:723\u201335.","journal-title":"N Engl J Med"},{"key":"1516_CR115","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1182\/blood-2021-149205","volume":"138","author":"Y Ginzburg","year":"2021","unstructured":"Ginzburg Y, Kirubamoorthy K, Salleh S, Lee SE, Lee JH, Selvaratnam V, et al. Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic Phlebotomy. Blood. 2021;138:390.","journal-title":"Blood"},{"key":"1516_CR116","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1200\/JCO.2022.40.16_suppl.7003","volume":"40","author":"R Hoffman","year":"2022","unstructured":"Hoffman R, Ginzburg Y, Kremyanskaya M, Khanna S, Modi N, Valone FH, et al. Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients. J Clin Oncol. 2022;40:7003.","journal-title":"J Clin Oncol"},{"key":"1516_CR117","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1182\/blood-2022-163755","volume":"140","author":"S Verstovsek","year":"2022","unstructured":"Verstovsek S, Kuykendall A, Hoffman R, Koschmieder S, Passamonti F, Valone F, et al. Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in patients with Polycythemia Vera. Blood. 2022;140:3929\u201331.","journal-title":"Blood"},{"key":"1516_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2025.108132","volume":"159","author":"LP Chew","year":"2025","unstructured":"Chew LP, Ginzburg YZ, Kirubamoorthy K, Lee SE, Lee JH, Modi NB, et al. Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera. Leuk Res. 2025;159:108132.","journal-title":"Leuk Res"},{"key":"1516_CR119","doi-asserted-by":"crossref","unstructured":"Kremyanskaya M, Ginzburg YZ, Hoffman R. Modulators of the Hepcidin Pathway in Polycythemia Vera and Myelofibrosis. Blood. 2025.","DOI":"10.1182\/blood.2025028643"},{"key":"1516_CR120","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1182\/blood-2025-2053","volume":"146","author":"N Gangat","year":"2025","unstructured":"Gangat N, Tefferi A, Gerds A, Grunwald M, Halpern A, Michaelis L, et al. A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV). Blood. 2025;146:2053.","journal-title":"Blood"},{"key":"1516_CR121","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/978-3-031-92033-2_26","volume":"1480","author":"A Nai","year":"2025","unstructured":"Nai A, Silvestri L, Asperti M, Vinchi F. Current Landscape of Hepcidin Therapeutics. Adv Exp Med Biol. 2025;1480:399\u2013418.","journal-title":"Adv Exp Med Biol"},{"key":"1516_CR122","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-017-0427-x","volume":"10","author":"S Vadhan-Raj","year":"2017","unstructured":"Vadhan-Raj S, Abonour R, Goldman JW, Smith DA, Slapak CA, Ilaria RL Jr, et al. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017;10:73.","journal-title":"J Hematol Oncol"},{"key":"1516_CR123","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood-2024-207686","volume":"144","author":"J Xu","year":"2024","unstructured":"Xu J, MacDonald B, Quisel J, Wu M. Anti-Hemojuvelin Monoclonal Antibody Alleviated Anemia Induced By Ruxolitinib Treatment in Mice. Blood. 2024;144:1752.","journal-title":"Blood"},{"key":"1516_CR124","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1182\/blood.V78.11.3066.3066","volume":"78","author":"E Juvonen","year":"1991","unstructured":"Juvonen E, Ikkala E, Fyhrquist F, Ruutu T. Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood. 1991;78:3066\u20139.","journal-title":"Blood"},{"key":"1516_CR125","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0140-6736(93)92558-B","volume":"341","author":"A de la Chapelle","year":"1993","unstructured":"de la Chapelle A, Sistonen P, Lehvaslaiho H, Ikkala E, Juvonen E. Familial erythrocytosis genetically linked to erythropoietin receptor gene. Lancet. 1993;341:82\u20134.","journal-title":"Lancet"},{"key":"1516_CR126","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/humu.22448","volume":"35","author":"C Bento","year":"2014","unstructured":"Bento C, Percy MJ, Gardie B, Maia TM, van Wijk R, Perrotta S, et al. Genetic basis of congenital erythrocytosis: mutation update and online databases. Hum Mutat. 2014;35:15\u201326.","journal-title":"Hum Mutat"},{"key":"1516_CR127","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/ajh.27311","volume":"99","author":"J Song","year":"2024","unstructured":"Song J, Lanikova L, Kim SJ, Papadopoulos N, Meznarich J, Constantinescu SN, et al. Novel germline JAK2(R715T) mutation causing PV-like erythrocytosis in 3 generations. Amelioration by Ropeg-Interferon. Am J Hematol. 2024;99:1220\u20139.","journal-title":"Am J Hematol"},{"key":"1516_CR128","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/bjh.18320","volume":"198","author":"PWW Tun","year":"2022","unstructured":"Tun PWW, Buka RJ, Graham J, Dyer P. Heterozygous, germline JAK2 E846D substitution as the cause of familial erythrocytosis. Br J Haematol. 2022;198:923\u20136.","journal-title":"Br J Haematol"},{"key":"1516_CR129","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1182\/blood-2023-186571","volume":"142","author":"I M\u2019Hiri","year":"2023","unstructured":"M\u2019Hiri I, Chin-Yee B, Bhai P, Wang A, Ho J, Lazo-Langner A, et al. SH2B3 Mutations in Patients with JAK2-Negative Erythrocytosis. Blood. 2023;142:5210.","journal-title":"Blood"},{"key":"1516_CR130","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMoa073123","volume":"358","author":"MJ Percy","year":"2008","unstructured":"Percy MJ, Furlow PW, Lucas GS, Li X, Lappin TR, McMullin MF, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med. 2008;358:162\u20138.","journal-title":"N Engl J Med"},{"key":"1516_CR131","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1006\/bcmd.2002.0488","volume":"28","author":"SO Ang","year":"2002","unstructured":"Ang SO, Chen H, Gordeuk VR, Sergueeva AI, Polyakova LA, Miasnikova GY, et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis. 2002;28:57\u201362.","journal-title":"Blood Cells Mol Dis"},{"key":"1516_CR132","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1182\/blood-2018-03-838235","volume":"132","author":"M Lenglet","year":"2018","unstructured":"Lenglet M, Robriquet F, Schwarz K, Camps C, Couturier A, Hoogewijs D, et al. Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. Blood. 2018;132:469\u201383.","journal-title":"Blood"},{"key":"1516_CR133","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.3324\/haematol.2014.109306","volume":"99","author":"N Petousi","year":"2014","unstructured":"Petousi N, Copley RR, Lappin TR, Haggan SE, Bento CM, Cario H, et al. Erythrocytosis associated with a novel missense mutation in the BPGM gene. Haematologica. 2014;99:e201\u20134.","journal-title":"Haematologica"},{"key":"1516_CR134","doi-asserted-by":"crossref","unstructured":"McMullin MF. Genetic Background of Congenital Erythrocytosis. Genes. 2021;12.","DOI":"10.3390\/genes12081151"},{"key":"1516_CR135","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1182\/blood.2020008424","volume":"137","author":"M Filser","year":"2021","unstructured":"Filser M, Giansily-Blaizot M, Grenier M, Monedero Alonso D, Bouyer G, P\u00e9r\u00e8s L, et al. Increased incidence of germline PIEZO1 mutations in individuals with idiopathic erythrocytosis. Blood. 2021;137:1828\u201332.","journal-title":"Blood"},{"key":"1516_CR136","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1709064","volume":"378","author":"J Zmajkovic","year":"2018","unstructured":"Zmajkovic J, Lundberg P, Nienhold R, Torgersen ML, Sundan A, Waage A, et al. A gain-of-function mutation in EPO in familial Erythrocytosis. N Engl J Med. 2018;378:924\u201330.","journal-title":"N Engl J Med"},{"key":"1516_CR137","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1056\/NEJMoa2414954","volume":"392","author":"L Martin","year":"2025","unstructured":"Martin L, Maric D, Idriss S, Delamare M, Le Roy A, Maaziz N, et al. Identification of Hepatic-like EPO as a cause of Polycythemia. N Engl J Med. 2025;392:1684\u201397.","journal-title":"N Engl J Med"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01516-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01516-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01516-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:04:16Z","timestamp":1783353856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01516-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":137,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01516-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}